Status:
COMPLETED
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Metastasis
Eligibility:
FEMALE
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Nolvadex (tamoxifen) as first-line treatment for postmenopausal women with advanced breast cancer. Patients will be tr...
Eligibility Criteria
Inclusion
- Biopsy confirmation of breast cancer. Evidence of breast cancer that is not considered amenable to curative treatment.
- Postmenopausal women. Written informed consent to participate in the study.
Exclusion
- Previous treatment with hormonal therapy unless that therapy was tamoxifen for adjuvant breast cancer. The use of tamoxifen must have ceased at least one year before this study.
- Previous treatment with Faslodex. Any existing serious disease, illness, or condition that will prevent participation or compliance with the study procedures.
- Treatment with an investigational or non-approved drug within one month of then start of the study.
Key Trial Info
Start Date :
November 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00241449
Start Date
November 1 1998
End Date
January 1 2012
Last Update
June 6 2012
Active Locations (139)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Little Rock, Arkansas, United States
2
Research Site
Fountain Valley, California, United States
3
Research Site
La Jolla, California, United States
4
Research Site
Orange, California, United States